-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical company Regeneron said recently that the FDA has extended its review of the Biologics License Application (BLA) for REGEN-COV (casirivimab and imdevimab) by three months, with a decision on July 13
FDA Prevention
The FDA first granted REGEN-COV Emergency Use Authorization (EUA) in late 2020 for the treatment of mild to moderate COVID-19 in adults and high-risk pediatric patients .
COVID-19 in children
In November, before the surge in Omicron, Regeneron reported the results of an analysis of nearly 1,700 people who lived in the same households as those diagnosed with COVID-19 in the previous four days
Findings from the Diagnostic Infection study showed that a single dose of REGEN-COV reduced the risk of contracting COVID-19 by 81.
Casirivima and imdevimab are monoclonal antibodies that specifically target the SARS-CoV-2 spike protein and are designed to prevent the virus from attaching to and entering human cells
Original source:
Original source:https://firstwordpharma.
https://firstwordpharma.
com/story/5549423 https://firstwordpharma.
com/story/5549423
Leave a comment here